February 25, 2019
SanBio President Keita Mori SanBio, a biotech specializing in regenerative therapies, will not yet give up its stem cell therapy SB623, which failed to hit its primary endpoint in a US PIIb study for chronic ischemic stroke, President Keita Mori...read more